CN1566108A - Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof - Google Patents
Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof Download PDFInfo
- Publication number
- CN1566108A CN1566108A CN 03128286 CN03128286A CN1566108A CN 1566108 A CN1566108 A CN 1566108A CN 03128286 CN03128286 CN 03128286 CN 03128286 A CN03128286 A CN 03128286A CN 1566108 A CN1566108 A CN 1566108A
- Authority
- CN
- China
- Prior art keywords
- extract
- red clover
- alcohol
- elutriant
- aliphatic alcohols
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof, the preparation of the extract comprises extracting red clover extraction liquid, reclaiming alcohol medium, passing column, eluting with alcohol solvent, reclaiming the elution liquid, processing the deposition with low level fat alcohol or acetone, obtaining the deposition and drying.
Description
Technical field
The present invention relates to Herba Trifolii Pratentis extract and preparation and the application in the pharmaceutical purpose composition thereof.
Background technology
Along with the progress and development of society, the raising gradually of people's living standard, also more and more higher to the requirement of quality of life.And give patient and family painful greatly with the diseases such as male prostatic hyperplasia that enter aged society based on the female dimacteric syndrome of a series of autonomic nervous dysfunctions and affective disorder.Have 70% menopausal women that the climacteric syndrome shape is arranged among the women approximately, what symptom was more serious accounts for 10～30%, and it is involutional for up to 10 years, and more serious symptom appears in 10～15% women, must treatment.The women 70% of western developed country more than 45 years old adopts Hormone Replacement Therapy, at least need serve on 8～10 years, can alleviate involutional symptom though take amcinonide for a long time, secular hormonotherapy has the increase genital system tumor, the danger of thrombosis and weight increase.Current research shows, no matter the oestrogenic hormon of single usefulness, still female, progestogen share, and the total incidence of mammary cancer increases by 60～85%, and the non-lobular carcinoma initiation potential of mammary gland increases by 50%.There is the potential pathogenic risk in the Hormone Replacement Therapy that studies show that of NIH (NIH).
With advancing age, prostatic diseases is a kind of very general disease, and more than half between U.S. 60～70 years old suffer from prostatoplasia diseases, and the 90% above male sex has prostatomegaly between 70～90 years old.Though the pharmacological agent of prostatomegaly and operative treatment are all effective in cure, often produce some side effects, cost an arm and a leg, particularly operative treatment may cause sexual dysfunction.Go up according to this reason, that people have turned one's attention to is inexpensive, low toxicity, the effectively exploitation of plant amedica, and Herba Trifolii Pratentis extract is a kind of active drug or food supplement for the treatment of climacteric syndrome and prostatomegaly of recent development.
A large amount of clinical studyes show that Herba Trifolii Pratentis extract improves significantly to the hectic fever of climacteric women, night sweat etc.; Regulating blood fat have the title of " blood street cleaner "; Bone density improving; Suppress hyperplasia of prostate, thereby improve symptoms such as urgent urination due to the prostatomegaly, frequent micturition, odynuria.
Red clover is extensive use of as herbal medicine and foodstuff additive respectively in states such as Europe, the United States, is mainly used in diseases such as rheumatosis, sacroiliitis, eczema, dermatitis, Whooping cough, climacteric syndrome and prostatomegaly antitumor, CCD.
The exploitation of red clover has in recent years also caused the attention of some research and development units of China, red clover distributes very wide in China, mainly contain Biochanin A (BiochaninA) and B (Formononetin Formononetin), genistein (Genistein), daizeol (daidzein), trifolirhizin (trifolirhizin) and red clover root element flavone components such as (pratensein).Biochanin A, B and genistein, daizeol all have estrogen effect.In the various isoflavone compounds, Biochanin A, B are the main components of this plant.According to statistics, the domestic research paper of delivering about red clover is less, the only research of assay and finger printing aspect, and have crude extract to export states such as America and Europe.The content of total isoflavone mostly is 8%, 10%, 20% in its crude extract, retrieves documents and materials both domestic and external, and the report of relevant its production technique is also few, adopts aqueous pure solvent extraction, exsiccant crude extract more.The product of general flavone content 〉=50% is not seen as yet, and its preparation process does not appear in the newspapers yet.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, on the basis of conventional extracting method, increase process refining, purifying, remove some non-active ingredients, highly enriched its activeconstituents-total isoflavone, thus the dose of minimizing medicine reduces adverse drug reaction.Consider the isoflavone compounds poorly water-soluble in addition, intend adopting micronizing, solid dispersion technology, increase its bioavailability.For this reason, provide a kind of red clover total flavones high-content extract and preparation and the application in the pharmaceutical purpose composition thereof.
Red clover total flavones high-content extract of the present invention is the effective part extract based on the total isoflavone of red clover, be characterized in that content of total flavone is 50-90% in the extract, wherein Formononetin (Formononetin) content is 25-70%, and Biochanin A (BiochaninA) content is 5-25%.
Preparation contains the method for the extract of red clover total isoflavones 50～90%, and its preparation process is as follows:
A. obtain the red clover extracting solution with conventional hydrous alcohol extraction, reclaim pure solvent, adding water or pure solvent then, to make its volume be 4～6 times of medicinal material volumes, and determining alcohol 10～60% filters, filtrate,
B. filtrate flow is through being filled with the adsorption column of sorbing material, and the sorbing material of filling is selected from any in polymeric amide, macroporous resin, the silica gel,
C. be that packing material 10-15 water wash adsorption column doubly is extremely colourless with volume,
D. with the C that contains 20～70%
1～4The lower aliphatic alcohols eluant solution is collected elutriant, and effluent volume is 14-16 times (as follows) of packing material,
E. concentrate and reclaim elutriant, get thick paste,
F. use 10～80% C
1～4Lower aliphatic alcohols or acetone stage treatment must be separated out throw out, are drying to obtain the extract that contains red clover total isoflavones 50-90%.
With extract obtained employing solid dispersion technology or micronizing, make its extract be molecularity or micron or nanoscale powder.
Described elutriant C
1～4Lower aliphatic alcohols is preferably ethanol or methyl alcohol.
The determining alcohol optimum range of described upper prop extracting solution is 40～55%,
The determining alcohol preferred range of described elutriant is 30～60%,
The determining alcohol optimum range of described elutriant is 40～55%,
The lower aliphatic alcohols of described stage treatment or acetone optimum concn 20～70%,
The lower aliphatic alcohols of described stage treatment or acetone optimum concn 30～45%,
Among the present invention, term " alcoholic solution " is meant methyl alcohol, the aqueous solution of ethanol or acetone.
Among the present invention, prepared Herba Trifolii Pratentis extract perhaps after solid dispersed or micronizing, adds an amount of auxiliary material and is prepared into and is used for climacteric syndrome and closes disease, oestrogenic hormon is low, male prostate is loose oral preparations.Extract can be refined into tablet (plain sheet, coated tablet, film coated tablet), capsule (hard capsule, soft capsule), granule, dripping pill with conventional pharmaceutical excipient hybrid process.Pharmaceutical excipient is meant weighting agent, tackiness agent, disintegrating agent, lubricant and coating material thereof and is used for the plant oil of soft capsule, fats weighting agent.
The quality of using the present invention to prepare the extract of other method preparation of Herba Trifolii Pratentis extract and use is compared as follows:
The mass ratio of former extract of table 1 and extract of the present invention
| Sample | Proterties | Total isoflavone content (%) | Formononetin (%) | Biochanin A (%) |
| Former extract | Brown, easily moisture absorption caking is paste | ??8 ??10 ??20 | ?3.15 ?- ?- | ?5.15 ?- ?- |
| The present invention | Pale yellow powder | ??≥50 | ?25～70 | ?5～25 |
The pharmacodynamic study of the made extract of the present invention:
A. the myelocytic influence of the skeletonization of tame rabbit bone marrow shows that extract is to rabbit medullary cell DNA, synthetic and the alkaline phosphatase activities of collagen protein etc. all has different promoter actions, its effect is the relation that dosage-effect relies on mutually, in four metering groups of 2～16mg/L (in the amount of total isoflavone), the promoter action of 16mg/L group is the strongest.
B. to the influence of prematurity female mice developing womb
Choose 40 of Healthy female mouse, body weight is 11～13g, is divided into blank group and administration group.Dosage divides 250,500,750mg/kg (in total isoflavone), and the blank group gives the distilled water of equal volume, once a day, continuous 7 days, after the last administration the 2nd day, mouse was weighed, and animal is put to death in the cervical vertebra dislocation, cut open and get the uterus, precision is weighed, and calculates the uterus coefficient, relatively the difference of each group.The results are shown in Table 2.
The influence of table 2 pair prematurity female mice developing womb
| (X ± S) (only) is mg/10g (mg/kg.) for group N dosage uterus coefficient |
| Distilled water 10-14.53 ± 5.35 |
| Extract 10 250 16.70 ± 3.10 10 500 24.60 ± 7.80 **????????10??????750???????32.68±9.13 ** |
[notes] "
*": compare P＜0.05 with normal group; "
*": compare P＜0.05 with model group.
The table 2 middle and high dosage group of refining extract of red clover as can be known all can promote the growth in prematurity female mice uterus.Effect of gain and control group comparing difference be (P＜0.01) significantly
The refining extract of c red clover is to the metabolic effect of removal ovary rat fat.
Choose 60 of wistar rats, be divided into normal group, sham operated rats, model group, oestrogenic hormon group, high and low dose isoflavones group at random, totally 6 groups, 10 every group, each is organized and all gives common complete feed nursing every day, and drinking water is tap water.Modeling, except that normal group and sham operated rats, all the other respectively organize rat excision bilateral ovaries.The rat of sham operated rats repeats to extract the ovary step, but does not extract ovary.The normal rat group is left intact.After the operation, each organizes 1 week of rat normal diet, to recover wound.The beginning administration of the 2nd week of operation back continued for 6 weeks.Distilled water 10ml.kg is fed in normal group, model group and sham operated rats filling every day
-1The oestrogenic hormon group is irritated stomach nilestriol suspension weekly for 1 time, and dosage is 1mg.kg
-1Herba Trifolii Pratentis extract calculates with total isoflavone, and giving high dose group every day is 100mg.kg
-1, low dose group is 50mg.kg
-1Measure cholesterol in blood fat and the liver.The results are shown in Table 3, table 4.
Table 3 Herba Trifolii Pratentis extract is to the removal ovary Serum TC, and the effect of TG (X ± S)
N (only) TC/mg.dl
-1TG/mg.dl
-1
Normal group 10 2.76 ± 0.41 1.13 ± 0.43
Sham operated rats 10 3.05 ± 0.44 1.02 ± 0.49
Model group 8 3.69 ± 0.31
*0.32 ± 0.07
*
Oestrogenic hormon group 9 3.46 ± 0.47
*0.89 ± 0.25
*
High 100mg.kg
-18 2.58 ± 0.43
*0.51 ± 0.36
*
Low 50mg.kg
-19 3.41 ± 0.87
*0.37 ± 0.08
[notes] "
*": compare P＜0.05 with normal group; "
*": compare P＜0.05 with model group.
As shown in Table 3, normal group and sham operated rats rat TC do not have significant difference, and the TC of model group rat has raise 34% than normal group, and significant difference is arranged.The TC concentration of oestrogenic hormon group does not reduce, and TC concentration significantly falls in high dosage extract group, and has dropped to normal level.
Table 4 Herba Trifolii Pratentis extract is to removal ovary rat HDL, and the effect of LDL (X ± S)
N (only) HDL/mg.dl
-1LDL/mg.dl
-1
Normal group 10 0.67 ± 0.14 1.00 ± 0.18
Sham-operation 10 0.78 ± 0.18 1.01 ± 0.20
Model group 8 0.79 ± 0.16 1.21 ± 0.24
Oestrogenic hormon 9 0.71 ± 0.16 1.25 ± 0.24
High 100mg.kg
-18 0.57 ± 0.14 0.93 ± 0.23
Low 50mg.kg
-19 0.74 ± 0.18 0.93 ± 0.16
[notes] "
*": compare P＜0.05 with normal group; "
*": compare P＜0.05 with model group.
As shown in Table 4, each organizes rat HDL does not have the significance influence, and the high and low dose group can reduce LDL to normal level.
D. Herba Trifolii Pratentis extract is to the effect of lipid in the removal ovary rat liver.
Normal group and sham operated rats hTc do not have significant difference.The hTc of model group has increased nearly one times than normal group and sham operated rats.After giving estrin treatment, hTc has dropped to normal level, and the extract of high and low dose all can reduce hTc, hTG accumulating in liver.The results are shown in Table 5.
Table 5 Herba Trifolii Pratentis extract is to removal ovary rat hTC, and the effect of hTG (X ± S)
N (only) hTC/mg.g
-1HTG/mg.g
-1
Normal group 10 1.13 ± 0.16 5.51 ± 1.62
Sham-operation 10 1.09 ± 0.18 5.49 ± 0.78
Model group 8 2.02 ± 0.17
*9.03 ± 1.59
*
Oestrogenic hormon 9 1.13 ± 0.17
*4.47 ± 0.53
*
High 100mg.kg
-18 1.35 ± 0.25
* ' * *6.46 ± 1.50
*
Low 50mg.kg
-19 1.62 ± 0.20
* ' * *6.67 ± 1.43
*
[notes+] "
*": compare P＜0.05 with normal group; "
*": compare P＜0.05 with model group.
In addition, this extract suppresses effects such as hyperplasia of prostate and anti-inflammatory in addition.More than preliminary pharmacodynamics confirm that the refining extract of red clover is that the prepared extract of the present invention has effects such as more weak estrogen effect, lipopenicillinase, bone density improving, be worth further research and development.
Embodiment
Embodiment 1
Aqueous alcohol solvent with routine extracts, and gets red clover medicinal material 1Kg, is cut into the long segment of 1-2cm or is ground into meal, extract with 15 times of aqueous ethanol solvents of amount of medicinal material weight, get extracting solution (following identical), reclaim under reduced pressure alcohol solvent is to alcohol concn 10%, standing over night filters, and gets filtrate.
Ordinary method is made extracting solution, the adsorption column of flowing through and filling with polymeric amide, at first doubly measure (the multiple of adsorption column filling adsorption material volume with 10-15, water wash down together) is to colourless, again with 16 times of amount 20% methanol-eluted fractions, decompression and solvent recovery, get thick paste, carry out stage treatment with 10% methyl alcohol, get throw out, be drying to obtain red clover total flavones high-content extract.Heavy 8g, yield 0.8%, extract are through determined by ultraviolet spectrophotometry total isoflavone 51.2%, and HPLC measures Biochanin A 13%; Formononetin 31%.
Embodiment 2
Aqueous ethanol solvent with routine obtains the red clover extracting solution, reclaims pure solvent to determining alcohol 30%, and standing over night filters, and gets filtrate.
With the adsorption column that reserve liquid is flowed through and filled with macroporous resin, at first extremely colourless with 10-15 water wash doubly, again with 15 times of amount 50% methanol-eluted fractions, decompression and solvent recovery gets thick paste, carries out stage treatment with 40% methyl alcohol, get throw out, be drying to obtain red clover total flavones high-content extract.Heavy 7.5g, yield 0.75%, extract are through determined by ultraviolet spectrophotometry total isoflavone 58.3%, and HPLC measures Biochanin A8%; Formononetin 39.3%.
Embodiment 3
Aqueous ethanol solvent with routine obtains the red clover extracting solution; Reclaim pure solvent to determining alcohol 55%, standing over night filters, and gets filtrate.
Reserve liquid is flowed through with the adsorption column of polymeric amide filling; At first the water wash of doubly measuring with 10-15 is used 70% ethanolic soln wash-out again to colourless, collects elutriant and reclaims pure solvent; Get thick paste, carry out stage treatment, get throw out, be drying to obtain red clover total flavones high-content extract with 80% alcohol solvent.Heavy 5.4g, yield 0.54%, extract are through determined by ultraviolet spectrophotometry total isoflavone 90.0%, and HPLC measures Biochanin A 5.4%; Formononetin 66.5%.
Embodiment 4
Aqueous ethanol solvent with routine extracts the red clover extracting solution that obtains, and reclaims solvent to containing determining alcohol 40%, and standing over night filters, and gets filtrate.
The adsorption column that reserve liquid is flowed through and filled with macroporous resin, at first the water wash of doubly measuring with 10-15 is to colourless, the ethanolic soln wash-out with 50%, the collection elutriant reclaims pure solvent; Get thick paste, carry out stage treatment, get throw out, promptly get red clover total flavones high-content extract with 35% acetone.Heavy 7.3g, yield 0.73%; Extract is through determined by ultraviolet spectrophotometry total isoflavone 61.2%, and HPLC detects Biochanin A12.5%; Formononetin 45.1%.
Embodiment 5
With embodiment 3 gained dry extracts, adopt the micronizing method to be ground into micron or nanoscale powder, to put among the PEG that has melted, treat that medicine is dispersed in the liquid carrier fully after, put in the drilling pill device, splash in the whiteruss, drip and make piller, every ball contains Herba Trifolii Pratentis extract 80mg.
Embodiment 6 contains producing of Herba Trifolii Pratentis extract tablet
Write out a prescription every: Herba Trifolii Pratentis extract 80mg
Microcrystalline cellulose 80mg
Starch 20mg
Lactose 18mg
Dextrin 2mg
Method for making: Herba Trifolii Pratentis extract and various auxiliary material mix; Use 80% alcohol granulation, whole grain; Encapsulated or compacting in flakes, every (sheet) 200mg.
Embodiment 7
Contain that Herba Trifolii Pratentis extract is capsular to be produced
Herba Trifolii Pratentis extract 80mg
Standamul G (medicinal plant oil) 120mg
Method for making: Herba Trifolii Pratentis extract is distributed in the Standamul G (medicinal plant oil), and is processed into soft capsule.
Embodiment 8
The producing of granule that contains Herba Trifolii Pratentis extract
Herba Trifolii Pratentis extract 80mg
Lactose 920mg
Method for making: Herba Trifolii Pratentis extract and lactose through pulverizing mix, with 70% ethanol system soft material, granulates, and whole grain, packing promptly gets (every pouch 1g).
Claims (11)
1, a kind of effective part extract based on red clover total isoflavones, it is characterized in that content of total flavone is 50-90% in the extract, wherein Formononetin (Formononetin) content is 25-70%, and Biochanin A (BiochaninA) content is 5-25%.
2, the described preparation method of extract of claim 1 is characterized in that preparation process is as follows:
A. obtain the red clover extracting solution with conventional hydrous alcohol extraction, reclaim pure solvent, adding water or pure solvent then, to make its volume be 4～6 times of medicinal material volumes, and determining alcohol is 10～60%, filter, filtrate,
B. the adsorption column of filtrate flow through being filled with sorbing material adsorbs, and the sorbing material of filling is selected from any in polymeric amide, macroporous resin, the silica gel,
C. be that packing material 10-15 water wash adsorption column doubly is extremely colourless with volume,
D. with the C that contains 20～70%
1～4The lower aliphatic alcohols eluant solution is collected elutriant, and effluent volume is 14-16 a times of packing material,
E. concentrate and reclaim elutriant, get thick paste,
F. use 10～80% C
1～4Lower aliphatic alcohols or acetone stage treatment must be separated out throw out, are drying to obtain the extract that contains red clover total isoflavones 50-90%.
3, method as claimed in claim 2, the determining alcohol that it is characterized in that described upper prop extracting solution is 40-55%.
4, method as claimed in claim 2 is characterized in that described elutriant C
1-4Lower aliphatic alcohols preferred alcohol or methyl alcohol.
5, method as claimed in claim 2, the determining alcohol that it is characterized in that described elutriant is 30-60%.
6, method as claimed in claim 2, the determining alcohol that it is characterized in that described elutriant is 40-55%.
7, method as claimed in claim 2 is characterized in that the lower aliphatic alcohols that described stage treatment is used or the concentration of acetone are 20-70%.
8, method as claimed in claim 2 is characterized in that the lower aliphatic alcohols that described stage treatment is used or the concentration of acetone are 30-45%.
9, the application of the described extract of claim 1 in the pharmaceutical purpose composition is characterized in that adding auxiliary material and is prepared into and is used for climacteric syndrome, oestrogenic hormon is low, male prostate is loose oral preparations.
10, the application of the described extract of claim 1 in the pharmaceutical purpose composition, it is characterized in that extract after solid dispersed or super-fine powder are broken into micron or nanoscale powder, add auxiliary material and be prepared into and be used for climacteric syndrome, oestrogenic hormon is low, male prostate is loose oral preparations.
11, as claim 9 or 10 application of described extract in the pharmaceutical purpose composition, it is characterized in that described oral preparations comprises tablet, soft capsule, hard capsule, granule, dripping pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03128286 CN1272332C (en) | 2003-07-07 | 2003-07-07 | Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03128286 CN1272332C (en) | 2003-07-07 | 2003-07-07 | Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1566108A true CN1566108A (en) | 2005-01-19 |
| CN1272332C CN1272332C (en) | 2006-08-30 |
Family
ID=34469191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03128286 Expired - Fee Related CN1272332C (en) | 2003-07-07 | 2003-07-07 | Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1272332C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314678C (en) * | 2005-06-09 | 2007-05-09 | 武汉联绎生物科技有限公司 | Method for extracting total isoflavone from herb of red clover |
| CN100554226C (en) * | 2006-04-20 | 2009-10-28 | 山东省医学科学院药物研究所 | The preparation method of the Herba Trifolii Pratentis extract of tool estrogen activity |
| CN1981799B (en) * | 2006-05-25 | 2010-11-10 | 湖南省中药提取工程研究中心有限公司 | Preparing method for extracts of red clover |
| CN102552241A (en) * | 2012-01-06 | 2012-07-11 | 南京中医药大学 | Application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma |
| CN108938712A (en) * | 2018-08-28 | 2018-12-07 | 新疆维吾尔自治区分析测试研究院 | Application of the chick pea extract in preparation treatment androgen-dependent disorders drug |
-
2003
- 2003-07-07 CN CN 03128286 patent/CN1272332C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314678C (en) * | 2005-06-09 | 2007-05-09 | 武汉联绎生物科技有限公司 | Method for extracting total isoflavone from herb of red clover |
| CN100554226C (en) * | 2006-04-20 | 2009-10-28 | 山东省医学科学院药物研究所 | The preparation method of the Herba Trifolii Pratentis extract of tool estrogen activity |
| CN1981799B (en) * | 2006-05-25 | 2010-11-10 | 湖南省中药提取工程研究中心有限公司 | Preparing method for extracts of red clover |
| CN102552241A (en) * | 2012-01-06 | 2012-07-11 | 南京中医药大学 | Application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma |
| CN108938712A (en) * | 2018-08-28 | 2018-12-07 | 新疆维吾尔自治区分析测试研究院 | Application of the chick pea extract in preparation treatment androgen-dependent disorders drug |
| CN108938712B (en) * | 2018-08-28 | 2021-04-27 | 新疆维吾尔自治区分析测试研究院 | Application of chickpea extract in preparation of medicines for treating androgen-dependent diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1272332C (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1515286A (en) | Chinese medicinal herb extractive | |
| CN101612362B (en) | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof | |
| CN1745843A (en) | Anticancer Chinese medicine compound preparation and its making method thereof | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN101057855A (en) | Medicinal composition containing epimedium active constituent and its application | |
| CN1272332C (en) | Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof | |
| CN1283281C (en) | Medicinal composition containing wild jujube seed, lucid ganoderma and ginseng leaf and its preparing process and use | |
| CN110664960B (en) | Traditional Chinese medicine composition for gastric mucosa precancerous lesion and preparation method and application thereof | |
| CN1216878C (en) | Process for preparing genistein, medicinal composition and use thereof | |
| CN101028317A (en) | Use of hypericum japonicum in preparation of medicine against nephritis and renal insufficiency | |
| CN1618441A (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN106110220B (en) | Preparation process of Chinese patent medicine for treating biliary tract diseases | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1895396A (en) | Chinese-medicinal preparation with Yin-nourishing, intestin-moistening and bowls-relaxing functions | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN1876097A (en) | Improved Chinese medicinal capsule for treating climacteric syndrome | |
| CN1931213A (en) | Tuniclike psammosilene root extract and its prep. medicine composition and use | |
| CN1175818C (en) | Extractive preparation containing total alkali of mulberry leaves and its preparing method | |
| CN109568419B (en) | Morinda officinalis total iridoid glycoside and preparation method and application thereof | |
| CN1132597C (en) | The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite | |
| CN1431221A (en) | Total saponin of polygara aureocauda dunn and madication combination as well as its preparing method | |
| CN1225262A (en) | Anti cancer drug contg. taxals alcohol | |
| CN1296083C (en) | Effervesce tablet of black-bone chicken and white phoenix, and preparation method | |
| CN1259950C (en) | Chinese medical preparation and its preparing process | |
| CN1557824A (en) | Silkworm excrement total alkaloid and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060830 Termination date: 20160707 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |